跳至主要内容
临床试验/ISRCTN70090382
ISRCTN70090382已完成不适用

Effects of a very low calorie diet (VLCD) induced weight loss on obstructive sleep apnoea syndrome (OSAS): a randomised controlled trial

Cambridge Manufacturing Company Limited (UK)0 个研究点目标入组 60 人开始时间: 2009年2月13日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • Amended as of 09/06/2009:
  • The following points of the below inclusion criteria have been amended:
  • 1. Patients with OSAS with an Apnoea-Hypopnea Index (AHI) greater than or equal to 15
  • 3. Aged between 30 and 65 years
  • All other inclusion criteria remain unaffected.
  • Initial information at time of registration:
  • 1. Patients with OSAS with an Apnoea-Hypopnea Index (AHI) between 15 and 60
  • 2. Male patients
  • 3. Age between 30 and 60 years
  • 4. Abdominal obesity with a Body Mass Index (BMI) 30-40 kg/m^2 and waist circumference >102 cm
  • 5. Signed informed consent to participate in the study

排除标准

  • 1. Contraindications for VLCD:
  • 1.1. Coronary thrombosis or myocardial infarct within the last three months
  • 1.2. Cerebro-vascular accident within the last three months
  • 1.3. Unstable ventricular arrhythmias
  • 1.4. Major surgery or trauma within the last three months
  • 1.5. Impaired renal or hepatic function
  • 1.6. Severe depression
  • 1.7. Use of mono-amine oxidase inhibitors (MAOIs)as anti-depressants
  • 1.8. Anorexia nervosa or bulimia nervosa
  • 1.9. Porphyria
  • 1.10. Milk protein allergy (the diet is milk based)
  • 1.11. Severe lactose intolerance (the diet is milk based)
  • 1.12. (Pregnant and lactating women, children below the age of 14)
  • 2. Drug treated diabetes
  • 3. Currently on a weight loss drug (Acomplia®, Reductil® or Xenical®)
  • 4. Bariatric surgery
  • 5. Recent angina pectoris or atrial fibrillation

研究者

发起方
Cambridge Manufacturing Company Limited (UK)

相似试验